Please login to the form below

Not currently logged in
Email:
Password:

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

Biogen

Biogen and Eisai have announced the rolling submission to the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) for lecanemab.

The submission, made as part of the accelerated approval pathway programme, is to use lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD with confirmed presence of amyloid pathology in the brain.

As part of the completed submission, Eisai has requested a priority review.

Results from the lecanemab phase 3 confirmatory ‘Clarity AD’ clinical trial, involving 1,795 patients, will be reported later in 2022.

The FDA has agreed that the results of Clarity AD, when completed, will serve as the study used to verify the clinical benefit of lecanemab. Dependent upon the results of this analysis, Eisai may submit for full approval at some point this year.

The BLA submission for lecanemab is based on clinical, biomarker and safety data from the proof-of-concept phase 2b trial involving 856 people with early AD.

The large number of participants across these studies provides the FDA with extensive safety data. After 18 months of treatment, lecanemab reduced brain amyloid by a mean of 0.306 SUVr units – from a baseline mean of 1.37 – and over 80% of subjects became amyloid negative by visual read.

In addition, the extent of reduction in amyloid was matched with slower clinical decline on both the Alzheimer’s Disease Composite Score and the Alzheimer Disease Assessment Scale-Cognitive Subscale.

“We would like to thank the people living with early AD and the healthcare professionals who participated in the lecanemab study and for their cooperation in allowing completion of this BLA to the US FDA. Alzheimer’s disease is a progressive and devastating disease with few treatment options,” said Haruo Naito, chief executive officer at Eisai.

“Eisai employees have spent time with people living with Alzheimer’s disease and their families to truly understand their feelings and challenges and have been working to create new treatments for many years. Our comprehensive medicine creation approach along the Alzheimer’s disease continuum reflects Eisai’s long-term commitment to providing innovative treatments to the people living with AD, their families and healthcare professionals who urgently need new treatment options,” he added.

Article by
John Pinching

10th May 2022

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...